COVID-19 Vaccine Candidate Heads To Widespread Testing In U.S.

Source: NPR

The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday, according to an NPR report.

Up to 30,000 volunteers will be assigned to one of two groups. One group will receive two injections spaced approximately 28 days apart of mRNA-1273, as the vaccine is known.

Read the full article.

Related Content